1992
DOI: 10.3109/03639049209040903
|View full text |Cite
|
Sign up to set email alerts
|

Erythrocytes as carriers of metronidazole: In-vitro characterization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0
1

Year Published

2008
2008
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(24 citation statements)
references
References 10 publications
0
23
0
1
Order By: Relevance
“…This method is based on the principle of first swelling the erythrocytes without lysis by placing them in slightly hypotonic solution. Drugs encapsulated in erythrocytes using this method include propranolol [33], asparginase [34], cyclophosphamide, cortisol-21-phosphate [32], 1-antitrypsin [27], methotrexate [27], insulin [35], metronidazole [36], levothyroxine [37], enalaprilat [38], and isoniazide [39]. Then, relatively small volumes of aqueous drug solution are added to the point of lysis.…”
Section: C) Preswell Methodsmentioning
confidence: 99%
“…This method is based on the principle of first swelling the erythrocytes without lysis by placing them in slightly hypotonic solution. Drugs encapsulated in erythrocytes using this method include propranolol [33], asparginase [34], cyclophosphamide, cortisol-21-phosphate [32], 1-antitrypsin [27], methotrexate [27], insulin [35], metronidazole [36], levothyroxine [37], enalaprilat [38], and isoniazide [39]. Then, relatively small volumes of aqueous drug solution are added to the point of lysis.…”
Section: C) Preswell Methodsmentioning
confidence: 99%
“…Several strategies have been attempted to overcome this problem with the use of membrane cross-linkers being the only successful one. [8][9][10][11][12] This strategy, however, suffers from the inclusion of foreign chemicals in the procedure, particularly, considering that these agents are potentially harmful to carrier cells life span in circulation via making their membranes more rigid compared with the normal cells. We, therefore, evaluated a novel strategy of using drug-loaded nanoparticles, instead of the "bare" drug for encapsulation in erythrocytes to solve the aforementioned problem.…”
Section: Introductionmentioning
confidence: 99%
“…They have a long ∼120-day lifespan in circulation, and this feature can be exploited in applications where slow and sustained cargo release into the intravenous circulation is desired. For example, erythrocytes have been used as circulating depots of vitamins 3 and steroids, 4-7 agents for antineoplastic, [8][9][10] antiparasitic, [11][12][13] and antiretroviral [14][15][16][17][18][19][20] therapies, and also as carriers for cardiovascular therapeutics. [21][22][23] Erythrocyte carriers are intrinsically biodegradable without the generation of toxic byproducts.…”
Section: Introductionmentioning
confidence: 99%